Skip to main content
SpringerLink
Log in
Book cover

Malignancies of the Genitourinary Tract pp 59–69Cite as

Endocrine Therapy of Advanced Prostatic Cancer

  • Conference paper

  • 42 Accesses

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 126))

Abstract

Even today, the majority of patients suffering from prostatic cancer have developed advanced stages of disease at the time of diagnosis. In fact, 40% already suffer from metastatic disease and have a 50% risk of dying within the first 2 years after diagnosis. Although there is already 50 years experience of hormonal treatment for advanced prostatic cancer the prognosis is still poor and a curative therapy is not available.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wilbert DM, Griffin JE, Wilson JD (1983) Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56:113

    Article  PubMed  CAS  Google Scholar 

  2. Farnsworth WE (1975) Human prostatic dehydroepiandrosterone sulfate sulfatase. In: Goland M (ed) Normal and abnormal growth of the prostate III. Thomas, Springfield

    Google Scholar 

  3. Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1:293

    CAS  Google Scholar 

  4. Scott WW, Menon W, Walsh PC (1980) Hormonal therapy of prostate cancer. Cancer 45:1929

    PubMed  CAS  Google Scholar 

  5. Blackard CE, Byar DP, Jordan WP Jr (1973) Veterans Administration Cooperative Urological Research Group: Orchiectomy for advanced prostatic carcinoma: a reevaluation. Urology 1:553

    Article  PubMed  CAS  Google Scholar 

  6. Chisholm GD (1985) Treatment of advanced cancer of the prostate. Semin Surg Oncol 1:38

    Article  PubMed  CAS  Google Scholar 

  7. Charig CR, Rundle JS (1988) Flushing: long-term sideeffects of orchidectomy in the treatment of carcinoma of the prostate. J Urol 139:478A

    Google Scholar 

  8. Debruyne FMJ, Denis L, Lunglmayer G (1988) Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 140:775

    PubMed  CAS  Google Scholar 

  9. Frödin T, Alund G, Varenhorst E (1985) Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 7:203

    Article  PubMed  Google Scholar 

  10. Iversen P, Hvidt V, Krarup T, Rasmussen F, Rose C (1988) The Danish protate cancer group: Zoladex plus flutamide vs. orchiectomy in patients with advanced prostatic cancer—a phase III study. Gynecol Endocrinol 2 [suppl 1]: 59

    Article  Google Scholar 

  11. Leuprolide study group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281

    Article  Google Scholar 

  12. Vugt DA van, Bakst G, Dyrenfurth I, Ferin M (1983) Naloxone stimulation of luteinizing hormone secretion in the female monkey: influence of endocrine and experimental conditions. Endocrinology 113:1858

    Article  PubMed  Google Scholar 

  13. Wehrenberg WB, Wardlaw SL, Frantz AG, Ferin M (1982) ß-endorphin in hypophyseal portal blood: variations throughout the menstrual cycle. Endocrinology 111:879

    Article  PubMed  CAS  Google Scholar 

  14. Dyer RG, Grossmann R: Mansfield S, Diez-guerra FJ, Bicknell RJ, Hollingsworth S (1988) Opioid peptides inhibit noradrenergic transmission in the preoptic area to block LH secretion: evidence from neonatally and rogenised rats. Brain Res Bull 20(6):721

    Article  PubMed  CAS  Google Scholar 

  15. Kalra SP, Simpkins JW (1981) Evidence for noradrenergic mediation of opioid effects on luteinizing hormone secretion. Endocrinology 109:776

    Article  PubMed  CAS  Google Scholar 

  16. Terasawa E, Krook C, Hei DL, Gearing M, Schultz NJ, Davis GA (1988) Norepinephrine is a possible neurotransmitter stimulating pulsatile release of luteinizing hormone-releasing hormone in the rhesus monkey. Endocrinology 123:1808

    Article  PubMed  CAS  Google Scholar 

  17. Cox B, Lomax P (1977) Pharmacologic control of temperature regulation. Annu Rev Pharmacol Toxicol 17:341

    Article  PubMed  CAS  Google Scholar 

  18. Claes H, Vanderbussche L, Vereecken RL (1987) Treatment of advanced carcinoma of the prostate by LHRH agonists. In: Murphy GP et al. (eds) Prostate cancer, part A: research, endocrine treatment, and histopathology. Liss, New York, p 229

    Google Scholar 

  19. Eaton AC, McGuire N (1983) Cyproterone acetate in treatment of post-orchidectomy hot flushes. Lancet (8363): 1336

    Article  Google Scholar 

  20. Altwein JE (1983) Estrogens in the treatment of prostatic cancer. In: Pavone-Macaluso M, Smith PH (eds) Cancer of the prostate and kidney. Plenum, New York, p 317

    Google Scholar 

  21. Sinha AA, Blackard CE, Seal US (1977) A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer 40:2836

    Article  PubMed  CAS  Google Scholar 

  22. Byar DP (1973) The VACURG studies of cancer of the prostate. Cancer 32:1126

    Article  PubMed  CAS  Google Scholar 

  23. Benson RC, Gill GM (1986) Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 9:341

    Article  PubMed  Google Scholar 

  24. Smith PH, Robinson M, Richards B (1984) Estramustine phosphate in prostate cancer. EORTC-Experience: preliminary results of protocol 30762. Urology 23 [Suppl]:64

    Article  PubMed  CAS  Google Scholar 

  25. VACURG (1967) Carcinoma of the prostate: treatment comparisons. J Urol 98:516

    Google Scholar 

  26. Prout GR Jr, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP, Young HH (1976) II. Endocrine changes after diethylstilbestrol therapy: effect on prostatic neoplasm and pituitary gonadal axis. Urology 7:148

    Article  PubMed  CAS  Google Scholar 

  27. Henriksson P, Edhag O (1986) Orchidectomy versus oestrogen for prostatic cancer. Cardiovascular effects. Br Med J 293:413

    Article  CAS  Google Scholar 

  28. Schally AV, Redding TW, Comaru-Schally AM (1983) Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate 4:545

    Article  PubMed  CAS  Google Scholar 

  29. Schally AV, Arimura A, Coy DH (1980) Recent approaches to fertility control based on derivatives of LHRH. In: Murson PL, Glover E, Deizfaluny E (eds) Vitamins and hormones. Academic, San Diego, p 257

    Google Scholar 

  30. Santen RJ, Bardin CW (1973) Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiological mechanisms. J Clin Invest 52:2617

    Article  PubMed  CAS  Google Scholar 

  31. Borgmann V, Nagel R, Schmidt-Gollwitzer M (1982) Langzeitsuppression der gonadalen Testosteronproduktion durch den LHRH-Agonisten Buserelinacetat (Hoe 766) beim fortgeschrittenen Prostatakarzinom—eine neue Therapieform? Aktuel Urol 13:200

    Article  Google Scholar 

  32. Wenderoth UK, Jacobi GH (1985) Langzeitergebnisse mit dem GnRH-Analogon Buserelin (Suprefact) bei der Behandlung des fortgeschrittenen Prostatakarzinoms seit 1981. Aktuel Urol 16:58

    Article  Google Scholar 

  33. Cassileth BR, Soloway MS, Vogelzang NH (1989) Patients’ choice of treatment in stage D prostate cancer. Urology 33 [Suppl]:57

    Article  PubMed  CAS  Google Scholar 

  34. Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P (1985) Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of the prostate. Urology 26:117

    Article  PubMed  CAS  Google Scholar 

  35. Leuprolide study group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281

    Article  Google Scholar 

  36. Aulitzky W, Frick J, Joos H, Hauser W (1987) Inhibition of LHRH-analogue induced testosterone surge by blockade of androgen receptors. J Urol 137:256A

    Google Scholar 

  37. Labrie F, Dupont A, Belanger A (1987) Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a LH-RH-agonist. J Urol 138:804

    PubMed  CAS  Google Scholar 

  38. Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, De-Jong FH, Klijn JG, Matroos AW, De-Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 137:912

    PubMed  CAS  Google Scholar 

  39. Schulze H, Senge T (1990) Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol 144:934

    PubMed  CAS  Google Scholar 

  40. Kuhn J-M, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis J-F, Costa P, Husson J-M, Dahan R, Bertagna C, Edelstein R (1989) Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321:413

    Article  PubMed  CAS  Google Scholar 

  41. Mowszowicz I, Bieber DE, Chung KW (1974) Synandrogenic and antiandrogenic effect of progestins: comparison with non-progestational antiandrogen. Endocrinology 95:1589

    Article  PubMed  CAS  Google Scholar 

  42. Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 42:282

    Article  Google Scholar 

  43. Neumann F, Hümpel M, Senge T, Schenck G, Tunn UW (1982) Cyproterone acetate—biochemical and biological basis for treatment of prostatic cancer. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer, vol 3. Williams and Wilkins, Baltimore, p 269

    Google Scholar 

  44. Trachtenberg J (1984) Ketoconazole therapy in advanced prostatic cancer. J Urol 132:61

    PubMed  CAS  Google Scholar 

  45. Williams G, Kerle DJ, Ware H (1986) Objective response to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 58:45

    Article  PubMed  CAS  Google Scholar 

  46. Worgul TJ, Santen RJ, Samojlik E (1983) Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol 129:51

    PubMed  CAS  Google Scholar 

  47. Neumann F, Habenicht UF, Schacher A (1984) Antiandrogens and target cell response—different in vivo effects of cyproterone acetate, flutamide and cyproterone. In: McKerns KW, Aakvaag A, Hansson V (eds) Regulation of target cell responsiveness, vol 2. Plenum, New York, p 489

    Google Scholar 

  48. Knuth UA, Hano R, Nieschlag E (1984) Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 59:983

    Article  Google Scholar 

  49. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S, members of the European Organization for Research of Treatment of Cancer Urological Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from european organization for research on treatment of cancer trials 30761 and 30762. J Urol 135:303

    PubMed  Google Scholar 

  50. Egle N, Altwein JE (1979) Postpuberal castration and prostatic carcinoma. Urology 6:471

    Article  Google Scholar 

  51. Raynaud JP, Bonne C, Moguilewski M (1984) The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate 5:299

    Article  PubMed  CAS  Google Scholar 

  52. Bruchovsky N (1980) Molecular action of androgens and antiandrogens. In: Hammerstein J, Lachnit Fixon U, Neumann F (eds) Androgenization in women. Excerpta Medica, Amsterdam, p 7

    Google Scholar 

  53. Walsh PC, Korenman SG (1971) Mechanism of androgenic action: effect of specific intracellular inhibitors. J Urol 105:850

    PubMed  CAS  Google Scholar 

  54. Neumann F (1981) Antiandrogens: pharmacology. In: Antihormone. Bedeutung in der Urologie. Klin Exp Urol 3:89

    CAS  Google Scholar 

  55. Lund F, Rasmussen F (1987) Flutamide versus stilbestrol in the management of advanced prostatic cancer. Br J Urol 61:140

    Article  Google Scholar 

  56. Asscheman H, Gooren LJG, de Voogt HJ (1987) Clinical and endocrinological results of short term Anandron treatment. Eur J Cancer Clin Oncol 23:1231

    Article  Google Scholar 

  57. Peets EA, Henson MF, Neri R (1974) On the mechanism of the antiandrogenic action of flutamide in the patient. Endocrinology 94:532

    Article  PubMed  CAS  Google Scholar 

  58. Furr BJA (1988) ICI 176334: a novel non-steroidal, peripherally-selective antiandrogen. In: Smith PM, Pavone-Macaluso M (eds) Management of advanced cancer of prostate and bladder. Liss, New York, p 13

    Google Scholar 

  59. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039

    PubMed  CAS  Google Scholar 

  60. Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, Sylvester R, De Pauw M, Vermeylen K, Ongena P, the EORTC Group (1990) Zoladex and flutamide versus bilateral orchiectomy. Cancer 66:1045

    PubMed  CAS  Google Scholar 

  61. Iversen P, Christensen MG, Friis E, Hornbøl P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P, Pedersen T, Rasmussen F, Rose C, Skaarup P, Wolf H (1990) A phase III trial of Zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66:1058

    PubMed  CAS  Google Scholar 

  62. Iversen P, Suciu S, Sylvester R, Christensen I, Denis L (1990) Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. Cancer 66:1067

    PubMed  CAS  Google Scholar 

  63. Schulze H, Isaacs J, Senge T (1987) Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J Urol 137:909

    PubMed  CAS  Google Scholar 

  64. Schulze H, Isaacs JT, Coffey S (1987) A critical review of the concept of total androgen ablation in the treatment of prostate cancer. In: Murphy GP et al. (eds) Prostate cancer, part B: imaging techniques, radiotherapy, chemotherapy and management issues. Liss, New York, p 1

    Google Scholar 

  65. Radlmaier A (1990) Theoretisches Modell über die Entstehung von Hitzewallungen. In: Nagel R (ed) Aktuelle Standortbestimmung der konservativen Therapie des Prostatakarzinoms. De Gruyter, Berlin, p 163

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Urologie, Marien-Hospital, Rhein-Ruhr-Universität, Widumer Strasse 8, W-4690, Herne, Germany

    R. Berges, H. Schulze & T. Senge

Authors
  1. R. Berges
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Senge
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik, Heinrich-Heine-Universität, Moorenstrasse 5, W-4000, Düsseldorf, Germany

    Rolf Ackermann

  2. Medizinische Klinik I, Universität Köln, Joseph-Stelzmann-Strasse 9, W-5000, Köln 41, Germany

    Volker Diehl

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Berges, R., Schulze, H., Senge, T. (1993). Endocrine Therapy of Advanced Prostatic Cancer. In: Ackermann, R., Diehl, V. (eds) Malignancies of the Genitourinary Tract. Recent Results in Cancer Research, vol 126. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84583-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84583-3_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84585-7

  • Online ISBN: 978-3-642-84583-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation